Armata Pharmaceuticals, INC 8-K filings

Armata Pharmaceuticals announced significant progress in clinical, regulatory, and manufacturing for its AP-SA02 phage therapy, supporting a planned Phase 3 study initiation in late 2026.

Armata Pharmaceuticals announced the promotion of David House to Chief Financial Officer and updated employment terms for Pierre Kyme, effective July 17, 2026.

Armata Pharmaceuticals announced it has received agreement from the FDA on an Initial Pediatric Study Plan for AP-SA02, a key regulatory step for its Staphylococcus aureus bacteremia treatment.

Armata Pharmaceuticals has appointed Dr. Daniel Gilmer to its Nominating and Corporate Governance Committee.

Armata Pharmaceuticals shareholders re-elected seven board members and ratified the appointment of Ernst & Young LLP.

Armata Pharmaceuticals announced a $25 million secured credit agreement with Innoviva and reported its first quarter 2026 financial results, highlighting progress on its lead therapeutic candidate AP-SA02.

Armata Pharmaceuticals announced its intravenously administered Staphylococcus aureus multi-phage product candidate, AP-SA02, has received U.S. FDA Fast Track Designation for adjunct treatment of complicated bacteremia.

Armata Pharmaceuticals announced the appointment of Dr. Daniel Gilmer to its Board of Directors, effective April 24, 2026.

Armata Pharmaceuticals has scheduled its 2026 annual meeting of stockholders for June 11, 2026.

Armata Pharmaceuticals announced its fourth quarter and full-year 2025 financial results, reporting a significant net loss and an audit opinion raising going concern doubts.

Armata Pharmaceuticals announced a delay in its Q4 and full-year 2025 financial results while providing significant updates on its lead bacteriophage therapeutic, AP-SA02.

Armata Pharmaceuticals announced its AP-SA02 product candidate received FDA Qualified Infectious Disease Product designation for complicated S. aureus bacteremia, offering significant development incentives.

Armata Pharmaceuticals, Inc. has secured extensions for its credit agreements, outstanding warrants, and a voting agreement with principal shareholder Innoviva Strategic Opportunities LLC.

Armata Pharmaceuticals announced FDA agreement to advance its AP-SA02 bacteriophage product into a Phase 3 superiority study for complicated Staphylococcus aureus bacteremia, marking a significant milestone for phage therapy.

Armata Pharmaceuticals, Inc. has entered into a Capital on Demand Sales Agreement to offer and sell up to $100 million of its common stock through an at-the-market offering program.

Armata Pharmaceuticals announced its Q3 2025 financial results and positive Phase 2a clinical data for AP-SA02 in complicated S. aureus bacteremia.

Armata Pharmaceuticals announced positive Phase 2a clinical trial results for its bacteriophage cocktail AP-SA02 in treating complicated Staphylococcus aureus bacteremia, paving the way for a pivotal Phase 3 study.

Armata Pharmaceuticals presents positive clinical data for its bacteriophage therapies, AP-SA02 and AP-PA02, highlighting significant efficacy and safety in treating serious bacterial infections.

Armata Pharmaceuticals secured a $15 million loan from Innoviva and announced positive Phase 1b/2a clinical trial results for its lead S. aureus therapeutic phage candidate, AP-SA02, alongside its second quarter 2025 financial results.

Armata Pharmaceuticals, Inc. announced that its shareholders elected seven directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as its independent auditor at the Annual Meeting held on June 12, 2025.

Armata Pharmaceuticals reports positive topline data from its Phase 1b/2a diSArm study of AP-SA02 in complicated Staphylococcus aureus bacteremia, showing improved clinical outcomes.

Armata Pharmaceuticals reported its Q1 2025 financial results, highlighting progress in clinical trials and securing additional funding.

Armata Pharmaceuticals receives $4.65 million in additional non-dilutive funding from the Department of Defense to advance its AP-SA02 clinical trial for Staphylococcus aureus bacteremia.

Armata Pharmaceuticals announces the date for its 2025 annual meeting of stockholders and related deadlines for stockholder proposals and director nominations.

Armata Pharmaceuticals reports encouraging Phase 2 results for AP-PA02 and secures a $10 million credit agreement to advance its bacteriophage therapeutics.

Armata Pharmaceuticals has entered into a $10 million secured credit agreement with Innoviva Strategic Opportunities LLC to further the development of its bacteriophage therapeutics.

Armata Pharmaceuticals reports encouraging topline results from its Phase 2 Tailwind study, demonstrating a significant reduction of Pseudomonas aeruginosa in the lungs of non-cystic fibrosis bronchiectasis patients using inhaled AP-PA02.

Armata Pharmaceuticals has finalized a separation agreement with its former Chief Medical Officer, Mina Pastagia, M.D., following her departure in November.

Armata Pharmaceuticals has extended its debt maturity dates to January 10, 2026, and appointed new leadership in finance and regulatory strategy as it prepares for Phase 3 clinical trials.

Armata Pharmaceuticals reported third quarter 2024 financial results and provided a corporate update, highlighting the completion of enrollment in two key clinical trials and securing additional funding.